2023
Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease
Godoy L, Farkouh M, Austin P, Shah B, Qiu F, Jackevicius C, Wijeysundera H, Krumholz H, Ko D. Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease. Journal Of The American College Of Cardiology 2023, 81: 2299-2311. PMID: 37316110, DOI: 10.1016/j.jacc.2023.04.021.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular SystemCoronary Artery DiseaseFemaleHeart FailureHumansMaleMyocardial InfarctionMyocardial IschemiaOntarioConceptsStable coronary artery diseaseCoronary artery diseaseBeta-blocker groupRecent myocardial infarctionHeart failureMyocardial infarctionCardiovascular eventsCoronary angiographyPrescription claimsObstructive coronary artery diseaseIndex coronary angiographyBeta-blocker therapyBeta-blocker useHeart failure hospitalizationElective coronary angiographyNew-user designMyocardial infarction hospitalizationsCause deathCardiovascular outcomesCause mortalityFailure hospitalizationCardioprotective benefitsArtery diseasePrimary outcomeIschemic heart
2017
Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs
Khazanie P, Al-Khatib SM, Wang TY, Crowley MJ, Kressin NR, Krumholz HM, Kiefe CI, Wells BL, O'Brien SM, Peterson ED, Sanders GD. Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. American Heart Journal 2017, 196: 170-177. PMID: 29421010, DOI: 10.1016/j.ahj.2017.07.022.Peer-Reviewed Original ResearchHow well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
Crowley MJ, Al-Khatib SM, Wang TY, Khazanie P, Kressin NR, Krumholz HM, Kiefe CI, Wells BL, O'Brien SM, Peterson ED, Sanders GD. How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research? American Heart Journal 2017, 196: 163-169. PMID: 29421009, DOI: 10.1016/j.ahj.2017.09.008.Peer-Reviewed Original ResearchConceptsOutcomes researchEarly career investigatorsCardiovascular Outcomes ResearchFunded grantsCost-effectiveness researchBlood InstituteNational HeartClinical epidemiologySystematic reviewPrior trainingCommunity-engaged researchResearch training programsDissemination researchInvestigator trainingCompetency areasObservational researchCore competency areasInvestigators' interestOutcomes researchersInvestigatorsTraining programHealth informaticsSimilar resultsLungEpidemiologyLiving Longer in Good Cardiovascular Health
Nasir K, Keeley B, Krumholz HM. Living Longer in Good Cardiovascular Health. Circulation 2017, 135: 1702-1704. PMID: 28461415, DOI: 10.1161/circulationaha.117.027960.Peer-Reviewed Original Research
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose